Risperidone: Regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain

Psychopharmacology

Volumn 124, Issue 1-2, 1996, Pages 74-86

  Hertel, Peter ^a   Nomikos, George G ^a   Iurlo, Marina ^a   Svensson, Torgny H ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antipsychotics; Frontal cortex; Microdialysis; Nucleus accumbens; Striatum

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; AMPEROZIDE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HOMOVANILLIC ACID; NEUROLEPTIC AGENT; RACLOPRIDE; RISPERIDONE; RITANSERIN; SEROTONIN; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOSE TIME EFFECT RELATION; MALE; MICRODIALYSIS; MONOAMINE METABOLISM; NEGATIVE SYNDROME; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SEROTONIN METABOLISM; SEROTONIN RELEASE; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CEREBRAL CORTEX; CLOZAPINE; CORPUS STRIATUM; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICRODIALYSIS; NUCLEUS ACCUMBENS; RACLOPRIDE; RATS; RATS, WISTAR; RISPERIDONE; SALICYLAMIDES; SEROTONIN; TIME FACTORS;

EID: 0029881945     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02245607     Document Type: Article

References (73)

1. 2 receptors: an autoradographic analysis in rat brain. Brain Res Bull 16: 517-525
2. Andén NE, Stock G (1973) Effects of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system. J Pharm Pharmacol 25:346-348
3. Andersson JL, Nomikos GG, Marcus M, Hertel P, Mathé JM, Svensson TH (1995) Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectively in the mesolimbic dopaminergic system. Naunyn Schmiedeberg's Arch Pharmacol 352:374-385
4. 2 receptors in the medial prefrontal cortex: microionlophoretic studies. Brain Res 506:346-348
5. Axelsson R, Nilsson A, Christensson E, Björk A (1991) Effects of amperozide in schizophrenía. Psychopharmacology 104: 287-292
6. Bartholini G (1976) Differential effect of neuroleptic drugs on dopamine turnover in the extrapyramidal and limbic systems. J Pharm Pharmacol 28:429-433
7. 2 receptor subtypes: a family re-united? Trends Pharmacol Sci 16: 105-110
8. Berman KF, Weinberger DR (1990) Prefrontal dopamine and defect symptoms in schizophrenia. In: Greden JF, Tandon R (eds) Negative schizophrenic symptoms: pathophysiology and clinical implications (Progress in Psychiatry Series vol. 28). American Psychiatric Press, Washington, DC, London. England, pp 81-95
9. 2 receptor blocking agent. Curr Ther Res 40:492-499
10. Björk A, Bergman I, Gustavsson G (1992) Amperozide in treatment of schizophrenic patients. A preliminary report. In: Meltzer HY (ed) Novel antipsychotic drugs. Raven Press, New York, pp 47-57
11. Borison RL, Parhiraja PA, Diamond BI, Meibach RC (1992) Risperidone: clinical satfey and efficacy in schizophrenia. Psychopharmacol Bull 28:213-218
12. Carboni E, Di Chiara G (1989) Serotonin release estimated by transcortical dialysis in freely moving animals. Neuroscience 32:637-645
13. Chiodo LA, Bunney BS (1983) Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopoaminergic neurons. J Neurosci 3:1607-1619
14. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13:25-40
15. Claghorn J, Honigfeld G, Abuzzahab FS, Wans R, Steinbook R, Tuason V, Klerman G (1987) The risk and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 7: 377-384
16. Coward DM (1992) General pharmacology of clozapine. Br J Psychiatry 160 [Suppl 17]: 5-11
17. 2-adrenoceptor antagonist Org 3770 enhances serotonin transmission in vivo. Eur J Pharmacol 253: R5-R6
18. Deutch AY, Moghaddam B, Innis RB, Krystal JH, Aghajanian GK, Bunney BS, Charney DS (1991) Mechanisms of action of atypical antipsychotic drugs: implications for novel therapeutic strategies for schizophrenia. Schizophr Res 4:121-156
19. 2 receptor antagonist, ritanserin. J Neurochem 59:1459-1466
20. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544
21. Ferré S, Artigas F (1995) Clozapine decreases serotonin extracellular levels in the nucleus accumbens by a dopamine receptor-independent mechanism. Neurosci Lett 187:61-64
22. Fink H, Morgenstern R, Oetssner W (1984) Clozapine a serotonin antagonist? Pharmacol Biochem Behav 20:513-517
23. Fitton A, Heel RC (1990) Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 40 [5]:722-747
24. Gelders YG (1989) Thymosthenic agents, a novel approach in the treatment of schizophrenia. Br J Psychiatry 155:33-36
25. 2 receptor blockers in the treatment of chronic schizophrenia. Clin Neuropharmacol 9:327-327
26. 2 receptor-mediated excitation of interneurons in piriform cortex: antagonism by atypical antipsychotic drugs. Neuroscience 58:515-525
27. Grenhoff J, Tung C-S, Ugedo L, Svensson TH (1990) Effects of amperozide, a putative antipsychotic drug, on rat midbrain dopamine neurons recorded in vivo. Pharmacol Toxicol 66 [suppl 1]:29-33
28. Hand TH, HU X-T, Wang RY (1987) Differential effects of acute clozapine and haloperidol on the activity of ventral tegmental (A10) and nigrostriatal (A9) dopamine neurons. Brain Res 415:257-269
29. Hillert A, Maier W, Wetzel H, Benkert O (1992) Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome a functional approach. Pharmacopsychiatry 25:213-217
30. Ingvar DH (1987) Evidence for frontal/prefrontal cortical dysfunction in chronic schizophrenia: the phenomenon of hypofrontality reconsidered. In: Helmchen H, Henn FA (eds) Biological perspectives of schizophrenia. Wiley, New York, pp 201-211
31. 2 antagonistic properties. J Pharmacol Exp Ther 244:685-693
32. Kahn RS, Davis KL (1995) New developments in dopamine and schizophrenia. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven Press, New York, pp 1193-1203
33. Kane J, Honigteld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45: 789-796
34. Krupp P, Barnes P (1992) Clozapine-associated agranulocytosis: risk and aetiology. Br J Psychiatry 160 [Suppl 17]:38-40
35. 2 antagonist. Mol Pharmacol 27:600-611
36. Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PAJ (1988) Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247:661-670
37. Leysen JE, Janssen PMF, Gommeren W, Wynants J, Pauwels PJ, Janssen PAJ (1992) In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol Pharmacol 41:494-508
38. 2 receptors. Psychopharmacology 112:S40-S54
39. Lindström E, Von Knorring L (1993) Changes in single symptoms and separate factors of the schizophrenic syndrome after treatment with risperidone or haloperidol. Pharmacopsychiatry 27: 108-113
40. Maidment NT, Marsden CA (1987) Acute administration of clozapine, thioridazine and metoclopramide increases extracellular DOPAC and decreases extracellular 5-HIAA, measured in the nucleus accumbens and striatum of the rat using in vivo voltammetry. Neuropharmacology 26:187-193
41. Mantz J, Godout R, Tassin J-P, Glowinski J, Thierry A-M (1990) Inhibition of spontaneous and evoked unit activity in the rat medial prefrontal cortex by mesencephalic raphe nuclei. Brain Res 524:22-30
42. 2 receptor occupation by typical and atypical antipsychotic drugs in vivo. J Pharmacol Exp Ther 265:498-508
43. Meltzer HY, Nash JF (1991) Effects of antipsychotic drugs on seroronin receptors. Pharmacol Rev 43:587-604
44. i values. J Pharmacol Exp Ther 251: 238-246
45. 2 receptor occupancy: implications for antipsychotic action. Eur J Pharmacol 216:67-71
46. Mesotten F, Suy E, Pietquin M, Burton P, Heylen S (1989) Therapeutic effect and saftey of increasing dose of risperidone (R64744) in psychotic patients. Psychopharmacology 99: 445-449
47. Moghaddam B, Bunney BS (1990a) Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 54:1755-1760
48. Moghaddam B, Bunney BS (1990b) Utilization of microdialysis for assessing the release of mesotelencephalic dopamine following clozapine and other antipsychotic drugs. Prog Neuropsychopharmacol Biol Psychiatry 14:S51-S57
49. Nomikos GG, Damsma G, Wenkstern D, Fibiger HC (1992) Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum. Neuropsychopharmacology 7:7-14
50. Nomikos GG, Iurlo M, Andersson JL, Kimura K, Svensson TH (1994) Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology 115: 147-156
51. Owens DGC (1994) Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry 55 [suppl 5]: 29-35
52. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. 2nd edn. Academic Press, London
53. Pazos A, Cortés R, Palacios JM (1985) Quantitative autoradiographic mapping of serolonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res 346:231-249
54. Pehek AA, Meltzer HY, Yamamoto BK (1993) The atypical antipsychotic drug amperozide enhances rat cortical and striatal dopamine efflux. Eur J Pharmacol 240: 107-109
55. Robertson GS, Matsumura H, Fibiger HC (1994) Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 271:1058-1066
56. Schotte A, Janssen PFM, Megens AAHP, Leysen JE (1993) Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res 631:191-202
57. Seeman P (1980) Brain dopamine receptors. Pharmacol Rev 32: 229-313
58. Seeman P, Lee T, Chau-Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261: 717-719
59. 2 antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther 266: 684-691
60. 2 receptor binding study of risperidone and haloperidol. Pharmacol Biochem Behav 47: 553-557
61. 2 receptor occupancy. Neuropsychopharmacology 12:57-64
62. 2 receptors as assessed by in vitro and in vivo binding. Eur J Pharmacol 254: 73-81
63. Svartengren J, Simonsson P (1990) Receptor binding properties of amperozide. Pharmacol Toxicol 66 [Suppl 1]:8-11
64. Svensson TH, Bunney BS, Aghajanian GK (1975) Inhibition of both noradrenergic and serotonergic neurons in brain by the α-adrenergic agonist clonidine. Brain Res 92:291-306
65. 2 antagonist ritanserin blocks the effect of pre-frontal cortex inactivation on rat A10 dopamine neurons in vivo. Acta Physiol Scand 136: 497-498
66. 2 antagonism. In: Vanhoutte PM, Saxena PR, Paolelti R, Brunello N, Jackson AS (eds) Serotonin. Kluwer Academic Publisher Dordrecht, and Fondazione Lorenzini, Milan, pp 263-270
67. 1-adrenoceptor antagonism. J Clin Psychopharmacol 15 [Suppl 1]:11-18
68. 2 receptor antagonist, activates inidbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology 98:45-50
69. Vandermaelen CP, Aghajanian GK (1983) Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurons recorded extracellularly in rat brain slices. Brain Res 289:109-119
70. Van Wielinck PS, Leysen JE (1983) Choise of neuroleptics based on in vitro pharmacology. J Drug Res 8:1984-1997
71. Weinberger DF (1987) Implications of normal brain development for the pathogenesis of Schizophrenia. Arch Gen Psychiatry 44: 660-669
72. White FJ, Wang RY (1983) Differential effect of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221:1054-1055
73. 2 agonist, DOI, on 5-HT neuronal firing in the dorsal raphe necleus and 5-HT release and metabolism in the frontal cortex. Br J Pharmacol 99:221-222